LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Search

BioCryst Pharmaceuticals Inc

Cerrado

SectorSanidad

8.56 -1.38

Resumen

Variación precio

24h

Actual

Mínimo

8.4

Máximo

8.71

Métricas clave

By Trading Economics

Ingresos

349M

362M

Ventas

247M

407M

Margen de beneficios

89.106

Empleados

580

EBITDA

234M

266M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+148.91% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

334M

1.9B

Apertura anterior

9.94

Cierre anterior

8.56

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

162 / 351 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 mar 2026, 23:39 UTC

Acciones populares

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Ganancias

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Ganancias

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Charlas de Mercado

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Charlas de Mercado

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Ganancias

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Ganancias

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Ganancias

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Ganancias

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Ganancias

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Charlas de Mercado

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Noticias de Eventos Importantes

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Charlas de Mercado

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Ganancias

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q Rev $19.31B >AVGO

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

148.91% repunte

Estimación a 12 Meses

Media 21.63 USD  148.91%

Máximo 32 USD

Mínimo 13 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

8

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

162 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.